Objective: To briefly review strategies aimed at the development of rotavirus and HPV vaccines, with emphasis on the current status of studies assessing the safety, reactogenicity, immunogenicity and efficacy of recently developed vaccines.
Introduction
The worldwide impact of diseases caused by rotavirus is extremely significant, both in developed countries and developing ones. 1 Multiple strategies resulted, leading from the pioneering Jennerian approach right up to the advent of vaccines now in phase III of trials or even to licensure of vaccines. The information that follows is a synthesis of the strategies adopted to date, with emphasis given to vaccines currently in testing or in the process of being licensed.
Pioneering strategies: brief historical background

Jennerian procedures
The first candidates for rotavirus vaccines were identified using a similar strategy to that used successfully by Edward Jenner more than two centuries ago. The pioneering experiments used the RIT 4237 and WC3 samples, both of bovine origin, which were tested in Finland and the USA, respectively. Although the efficacy levels achieved in those two countries were significant (> 80%), subsequent investigations in South America and Africa demonstrated frustratingly low protection, resulting in the abandonment of trials. 4 
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Next, several studies were undertaken using a viral sample of simian origin, RRV (or MMU 18006), serotype G3, with highly variables results. At this point, the theory that type-specific protection might be required led to the development of polyvalent preparations.
Modified Jennerian strategies
These strategies resulted in genetically restructured samples, taking advantage of the segmented nature of the viral genome by cocultivation of rotavirus from both animal and human origins. The proposal was to develop chimeras containing 10 rotavirus genes of animal origin and another from viral samples from humans. 5 Such preparations are basically composed of rotavirus strains resulting from the genetic permutations between the WC3 and RRV samples and the serotypes that infect humans.
The advent of the rhesus-human reassortant tetravalent vaccine (RRV-TV), of human-simian origin, occasioned innumerable and extensive studies in many countries. 1, [6] [7] [8] [9] The impressive level of efficacy achieved with this vaccine, in particular in Venezuela, were the basis for its license being granted in the USA in August 1998, under the trademark Rotashield ® (Wyeth Laboratories ® , Inc., Marietta, Pennsylvania). One year later, after it had been administered to 900,000 children, 15 cases of intussusception emerged as a possible severe adverse event associated with the vaccine, leading to its suspension. 10, 11 It was noted that 81% of these cases were in children older than 3 months, despite the fact that this age group accounted for less than half of the total vaccinated population. This evidence has resulted in recommendations for the new generation of vaccines that limit the age at administration of the first dose to 12 to 14 weeks. Nowadays there is consensus that 1 child in every 10,000 vaccinated with Rotashield ® is at risk of developing intussusception. 1, 12, 13 A second group of vaccines involved preparations of bovine (WC3 sample) and human origin, resulting in a tetravalent formulation to be given in three doses.
Studies of its efficacy indicated 67% protection from all
rotavirus-induced diarrhea episodes. 14 
Vaccine candidates of human origin
These procedures were based on the observation that repeated natural infections culminate in solid protection. 15 The first attempts involved rotavirus obtained from newborn infants in wards. The M37 sample, G1 type, isolated from a neonate in Venezuela, was the first candidate for a vaccine that resulted from these strategies. The insignificant efficacy rates achieved in tests in Finland, however, caused the discontinuation of studies with M37. 1
Current vaccine scenario: ongoing tests and licensure
The apparent failure of the tests involving the vaccine candidates described in the previous section, chiefly the suspension of Rotashield ® in the USA, culminated in unexpected delay. Nevertheless, decisive lessons were learnt that contributed to the current, auspicious, moment.
This situation was particularly well described by Glass et al., 16 in a recent article with the emblematic title The future of rotavirus vaccines: a major setback leads to new opportunities. Table 1 collects, in a synthesized manner, the basic characteristics of vaccines that are currently on trial or already licensed.
Below is a brief description of the characteristics of each vaccine in the current generation, undergoing clinical trials or duly licensed, with emphasis on RotaRix ® , which was recently licensed in some Latin American countries.
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This is a vaccine represented by attenuated rotavirus of ovine origin, serotype G10, produced by the Lanzhou Institute of Biological Products in China. Although it is licensed for wide-scale use in that country, reservations persist about the methodology employed during testing. 1, 4 RotaTeq ® This is a pentavalent vaccine preparation derived from the WC3 bovine sample, combining samples genetically restructured to be specific for G1, G2, G3, G4 and P1A [8] . This is a non-reactogenic product with elevated efficacy, achieving 100% protection against the most severe episodes of diarrhea. 17 Recently, phase III trials of RotaTeq ® were completed, involving at least 68,000 children, and, at the start of 2006, the vaccine was licensed by the Food and Drug Administration (FDA) in the USA. In addition to being free from intussusception risk, the vaccine has also proved itself 94.5% effective against hospitalizations and emergency consultations related to the G1 to G4 viral types, reduced gastroenteritis associated with these serotypes by 74% and demonstrated 98% protection from severe episodes caused by rotavirus. 18 
RotaRix ® (RIX4414 sample)
Worthy of special attention, among strategies involving attenuated rotavirus of human origin, is RotaRix ® (RIX4414 sample) by GlaxoSmithKline ® Biologicals (GSK), Rixensart, Belgium. This monovalent preparation, from the ranks of the multiple candidates for rotavirus vaccines, is now at an advanced stage of trials and has already been licensed in some South American countries and in Kuwait. 4 Testing of RIX4414 involved at least 72,000 children in 20 countries, in at least 15 different clinical trials. The results of these multiple analyses are described very briefly below.
Origin of the vaccine and precursor studies
The viral sample (originally designated 89-12) was isolated from the feces of a child in Cincinnati, Ohio, USA, who had moderate diarrhea. [19] [20] [21] Passage through cell cultures and cloning procedures resulted in the attenuated RIX4414 sample, specific for G1 (glycoprotein) and P [8] (protease sensitive protein). 21 The product currently in licensing is for oral use and is presented lyophilized in individual flasks with administration indicated between 2 and 4 months of age.
Pre-clinical testing of RIX4414 was undertaken in Finland, with aspects related to safety, immunogenicity and efficacy being investigated. 22 No significant side effects were observed and satisfactory immunoresponse was observed in 95% of susceptible children. 23 On the other hand, for clinically severe diarrhea episodes, protection was calculated as being in the order of 90%. 24 Extensive phase II trials of the RIX4414 vaccine Tolerance to the vaccine was assessed, noting the frequency of solicited symptoms for 15 days after each dose was administered. Percentages of fever, diarrhea, vomiting, irritability, anorexia and coughing/ coryza were comparable for all three vaccine concentrations and placebo ( Figure 1 ). 22, 25, 27 No relevant severe adverse events were observed, nor were there any deaths with causal links to vaccination, including intussusception.
Immunoresponse was also analyzed in the phase II trials in Latin America, in terms of the frequency of serological conversions expressed by immunoglobulin A specific for rotavirus. Figure 2 demonstrates a variation of 61 to 65% for the serum samples collected after the second dose, in clear contrast with the children given placebo.
On the subject of immunoresponse, it should be noted that the take of the vaccine a combination of serological conversion and excretion of the vaccine virus reaches 75% after two doses at the highest concentration, i.e. 10 5.8 PFU. 25, 27 Vaccines against rotavirus and HPV Linhares AC & Villa LL One well-publicized and practical aspect related to immunogenicity is the fact that when RIX4414 is administered concurrently with routine vaccines, there is no interference whatsoever with their immunoresponse. 22, 25, 27 Phase II specified an interval of 15 days between the administration of RIX4414 and the oral polio vaccine (OPV). Studies of the concurrent use of both, carried out in South Africa, provide evidence that the phenomenon of interference does not exist. 27 In general, efficacy rates are more significant for protection against severe diarrhea episodes, based on the Despite the vaccines monovalent character, heterotypic protection was also observed. In addition to the 88% efficacy for the G1 serotype, it has also become noteworthy for the protection (83%) it offers against other types in circulation, including G9, which is emerging on a global scale. 25 
UK bovine sample derivative
Another vaccine candidate based on genetic permutations between rotaviruses of animal and human origins is the tetravalent (G1, G2, G3 and G4) preparation derived from the UK sample, conceived by the NIH, USA.
Phase II trials indicate satisfactory levels of inocuity, efficacy and immunogenicity. 30, 31 Samples of neonatal origin (RV3, 116E and I32)
Currently appearing as monovalent rotavirus vaccine candidates are three samples isolated from newborn infants, one evaluated in Australia (RV3) and the other two in India (116E and I321). The RV3 sample has antigenic identity with the G3 viral type and is free from adverse reactions and moderately immunogenic. 1, 4 The 116E
(serotype G10) and I321 (G9) samples have immunogenic potential, in addition to the efficacy they exhibited against symptomatic rotavirus reinfection. 1, 4 
RRV-TV
The North-American company Biovirx ® is currently planning a possible return to production of Rotashield ® .
They claim that the benefits of the vaccine in developing countries considerably outweigh any possible risks represented by intussusception. Those that defend a return to RRV-TV production claim that the risks themselves were overestimated in analyses performed so far. 4
Prospects
Although the results from the two vaccines RotaRix ® and RotaTeq ® , based on live attenuated viruses, are promising, efforts continue to create new preparations for probable future use. Two that stand out are a simianhuman hexavalent formulation, 32 and another with a rotavirus of porcine origin as a substrate to be genetically rearranged with serotypes that infect humans. 33, 34 Possible vaccines of the future contain deactivated rotavirus (or viral fragments) which is, theoretically, free of any risk whatsoever of intussusception. 1
Vaccine against human papillomavirus (HPV)
Global estimates indicate that approximately 20% of More than 98% of cervical tumors are caused by these viruses. 36 The types present in these tumors are different from the ones found in benign lesions of the anogenital Infections by HPV are relatively common in normal individuals, varying from 20 to 40% depending on age and immune status, being more common in the young. Most of these infections are totally asymptomatic and regress spontaneously. 39 The risk of developing the disease is associated with persistent infections by high-oncogenic risk HPV types. 40 Therefore, any measure that controls HPV infections should have an impact on the control of pathologies linked to them. The first impact should be reflected in a reduction in the rates of precursor lesions, but the ultimate objective is to control the incidence of cervical cancer. Based on the administration of a vaccine with elevated efficacy, it could be estimated that a 75% reduction in the prevalence of type 16 HPV alone could signify a 75% drop in the incidence of cervical intraepithelial neoplasms (CIN). Thus, safe and effective vaccines against HPV could be important instruments in the prevention of cervical cancer worldwide, but particularly in developing countries.
Vaccines against animal papillomaviruses
Papillomaviruses are species specific and are not therefore transmitted between different animal species.
There is, however, a high level of similarity in the genomic structure of these viruses, which makes it possible to extrapolate to humans a series of features of the virushost relationship observed in animals, particularly with relation to the immunological aspects of these infections.
Noteworthy studies have involved rabbits, dogs and cows, and the viruses cottontail rabbit papillomavirus (CRPV), canine oral papillomavirus (COPV) and the many types of bovine papillomavirus (BPV). 41 At present the most effective vaccines are those that have been developed for use against CRPV and COPV. contained in the vaccines being tested. 42 There is much interest, therefore, in investigating the possibility of crossprotection, given the genetic similarity between the many different types of HPV. The ongoing clinical trials could provide information that is still lacking in this matter. 46 and the other a quadrivalent vaccine (6, 11, 16, 18) . 47 Both vaccines were shown to be safe, well tolerated by the young volunteers. Yet more important is that the immunoresponse triggered by both forms was extremely elevated, with antibody titers more than one hundred times higher than the levels observed in women of the same age group naturally exposed to the various HPVs being studied. Finally, in the two published clinical trials, the vaccines exhibited elevated efficacy, having controlled from 90 to 100% of infections by the HPV types included in the vaccines, in addition to preventing 95 to 100% of the lesions caused by these viruses. to confirming that the vaccine is safe, well tolerated and highly immunogenic, an efficacy rate of 100% was observed for the prevention of cervical cancer precursor lesions. 47 These excellent results supported the application to the be commercially available and will begin to be used in the USA and other countries that approve it.
Final comments
The primary goals of an international program for the development of vaccines against rotavirus specify an immunization program covering 60 to 80% of the worlds children in the next 10 years. Achieving this, it is estimated that the number of rotavirus related deaths and hospitalizations would be reduced by 50 to 60% globally. 3, 4 Notwithstanding, although there now exist real chances of achieving this objective, there are still obstacles to be overcome. While the two vaccines in the most advanced 
